உலகம் ஒவ்வாமை ஆர்கந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from உலகம் ஒவ்வாமை ஆர்கந். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In உலகம் ஒவ்வாமை ஆர்கந் Today - Breaking & Trending Today

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Symbicort approved in China for mild asthma

an anti-inflammatory reliever in mild asthma

therapy approved in China for mild, moderate and severe asthma

AstraZeneca s Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve asthma control in patients with mild asthma aged 12 years and older.

The approval by the National Medical Products Administration (NMPA) was based on positive results from the
SYGMA 1
and
SYGMA 2
Phase III trials, published in TheNew England Journal of Medicine, which evaluated the efficacy of Symbicort Turbuhaler taken as-needed as an anti-inflammatory reliever compared with standard of care (SoC) therapies in mild asthma. SoC included short-acting beta2-agonist (SABA) taken as-needed or regular maintenance controller therapy (twice-daily budesonide, an inhaled corticosteroi ....

United Kingdom , United States , Symbicort Turbuhaler , Buhlr Budesonide , Astrazeneca Symbicort Turbuhaler , Adrian Kemp , Astrazeneca Pharmaceuticals , Chinese Thoracic Society , International Study Group , Company On Twitter Astrazeneca , China Thoracic Society , Investor Relations Team , National Asthma Guidelines , National Medical Products Administration , Global Asthma Network , Blood Institute , National Heart , Global Initiative For Asthma , Thenew England Journal , Vice President , Shanghai General Hospital , Global Initiative , Executive Vice President , Symbicort Given , Mild Asthma , New England Journal ,

First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis

Search jobs
16-Dec-2020
First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis
New clinical trial also announced for Fasenra
in eosinophilic gastritis/eosinophilic gastroenteritis
The first patients have been dosed in
Fasenra (benralizumab) Phase III trials in three rare eosinophilic diseases: hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE) and eosinophilic granulomatosis with polyangiitis (EGPA)
AstraZeneca will also initiate a Phase III trial to investigate the potential of
Fasenra in an additional rare eosinophilic disease: eosinophilic gastritis/eosinophilic gastroenteritis (EG/EGE). This trial extends the
Fasenra clinical programme to nine diseases where eosinophils play an important role, in addition to severe asthma. ....

United Kingdom , United States , Clin Otolaryngol , Bachertc Biologics , Wechslerm Akuthota , Fujiedas Imoto , Pediatr Gastroenterol Nutr , Gastroenterol Hepatol , Company On Twitter , Glob Health Epidemiol Genom , Global Health Epidemiology Reference Group , Wales National , Biowa Inc , Kyowa Kirin Co Ltd , Global Initiative For Chronic Obstructive Lung Disease , Vasculitis Foundation , Drug Administration , Impact On Health , American Academy Of Allergy Asthma Immunology , Investor Relations Team , National Organisation For Rare Disorders , J Glob Health , American Partnership For Eosinophilic Disorders , Executive Vice President , Orphan Drug Designation , Churg Strauss Syndrome ,

Over-reliance on reliever pumps linked to increased risk of asthma attacks

Over-reliance on reliever pumps linked to increased risk of asthma attacks
citizen.co.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citizen.co.za Daily Mail and Mail on Sunday newspapers.

South Africa , United States , United Kingdom , Khomotso Mashilane , Rob Horne , Marlin Mckay , University College London , Goldman Medical Centre , Astrazeneca Pharmaceuticals , Astrazeneca United Kingdom , International Study Group , Community Pharmacy Association , National Asthma Education Programme , International Primary Care Respiratory Group , Global Asthma Network , Global Initiative For Asthma , Airways Patient Platform , Global Initiative , Doctor Marlin Mckay , Global Allergy , Independent Community Pharmacy Association , Break Over Reliance , Reliever Reliance , Medical Director , African Cluster , Reliever Reliance Test ,